Background
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects many facets of fertility. It is the cause of 18–25% of couples’ infertility. More patients with PCOS than those without the condition need assisted reproduction techniques (ARTs) therapy [1]. Despite recent advances in ARTs, allowing the selection of high-quality embryos, the implantation rate and live birth rate remain low and have not increased enough during in Vitro Fertilization (IVF) in recent decades [2].
Several reports have shown that gonadotropin stimulation in IVF treatment may change the endometrium and embryo quality, which may affect the live birth rate and embryo implantation [3, 4]. Horcajadas et al. found that more than 200 genes showed a differential endometrial gene expression of more than 3-fold when controlled ovarian hyperstimulation (COH) and normal cycles were compared at hCG + 7 versus LH + 7 [5]. Enhanced MAGEA11 and AR-mediated transcriptional regulation might impact a correct endometrial decidualization response and delay endometrial decidualization in PCOS [6]. Qiao et al. [7] used High-density oligonucleotide microarrays with 21,571 genes and found that the majority of the genes showing altered expression were down-regulated in endometrial samples from PCOS patients, especially those genes associated with membrane functions, extracellular matrix components, adhesion, invasive growth, and the cytoskeleton.
Anzeige
According to recent data, elective single blastocyst and single morula embryo transfer (ET) during in vitro fertilization embryo transfer (IVF-ET) produced similar clinical results [8‐10]. In addition to the cleavage and blastocyst ET, morula ET may serve as an alternative option for the clinician [11]. Even some laboratories believed that D4 ET can be chosen to avoid ET cancellation in D5 due to unfavorable conditions in the IVF laboratory, but the decremented quality of embryos for transfer and the decreased pregnancy rate must be taken into consideration [12]. Is there a difference between PCOS and no-PCOS in the number of days for the embryo transfer to be successful? If the best day for transfer can be determined, PCOS implantation and live birth rates would rise considerably. These should consider suitable embryo quality, embryo-endometrium synchronization, and optimization of gene expression changes during the implantation window for PCOS transplantation. This study aimed to fill this gap in the literature by evaluating the best transfer day for PCOS patients undergoing IVF.
Methods
Study design and subject screening
This retrospective cohort study was conducted in the Xingtai Infertility Specialist Hospital between January 2017 and November 2021. A total of 1,664 fresh ART cycles met inclusion criteria, including 242 PCOS transfers and 1422 tubal factor infertility transfers. We used the Rotterdam diagnostic Revised 2003 criteria (2 out of 3) in adults revised: (1) Oligo-or anovulation; (2) Clinical and/or biochemical signs of hyperandrogenism; (3) Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing’s syndrome) [13]. The selection of the study patients is shown in Fig. 1.
Fig. 1
The flow chart of the study population
×
![]()
The primary endpoint of this research was the fresh cycle clinical live birth rate, and the secondary endpoints were implantation rate, pregnancy rate, and miscarriage rate. There was no missing data in the study. Written approval for this study was obtained from the Ethics Board at Xingtai Reproduction and Genetics Specialist Hospital.
Anzeige
Ovarian stimulation
All patients received GnRH agonist pituitary down-regulation protocol. 1.0 to 3.75 mg of long-acting Duffelin (IPsen, France) were administered. Subsequently, recombinant follicle stimulating hormone (r-FSH, Precon, Merck, Netherlands) was administered from 100 to 225 IU/d. Transvaginal ultrasonography was used to regularly measure follicle size, and blood levels of progesterone, LH, and E2 were used to measure follicle growth. When at least two leading follicles were ≥ 18 mm, 6000-10,000 IU of human chorionic gonadotropin (Zhuhai Lizon Pharmaceutical) was injected. 36–37 h later, the oocytes were taken out.
Embryo culture
The oocyte collection and embryo culture system media used G-series (Vitrolife AB, Gothenburg, Sweden). All procedures were performed in standard incubators using 37℃, 6% CO2, and 5% O2 incubators.
After selective fertilization, one to two embryos were transplanted on D3/D4/D5 in accordance with the development of the embryos on D3 after fertilization. In our center, we grade embryos according to the 2011 ESHRE Istanbul Consensus and Ryh-sheng Li’s system [14], and blastocysts using the Gardner scoring system [15] as follows.
D3 embryos were assessed based on the number and blastomeres, the degree of fragmentation, and the presence of multinucleated cells. High-quality embryos were determined to have 7–8 cells, with 10% fragmentation. The available embryos were 6–10 cells, uneven blastomeres, and ≥ 10% fragmentation. They were both absence of multinucleated blastomeres.
D4 embryos, which lose all of the boundaries of the blastomere were classified as grade 1. Embryos with less than 100% but more than 50% of compaction will be rated as grade 2 [14]. The grade 1 was called high-quality embryo. And the grade 2 was called available-embryo.
The inner cell mass and trophectoderm quality of D5 embryos, whose growth and hatching status were assessed from grade 1 to grade 6, were both rated as A, B, and C [15]. The 4/5/6AA, 4/5/6AB, 4/5/6BA, and 4/5/6BB were called high-quality embryos. The 3AA/AB/BA/BB and 4/5/6BC/CB were called available embryos.
Women with overt ovarian hyperstimulation syndrome (OHSS) and thrombosis were not allowed to have embryo transplantation; The number of available embryos on the third day following fertilization determined which day to transfer. If the number of available embryos was equal to the number of transplants, the embryos were transplanted on D3. If the number of available embryos was higher than that of transplants, the early blastocysts or morulae were selected for transplantation on D4. The blastocysts were chosen and transplanted on D5 if there were more than four high-quality embryos available.
Definition of clinical outcomes
Serum β-hCG was detected 12–14 days after transplantation to determine whether it was a biochemical pregnancy. About four weeks after transplantation, the beat of the gestational sac and the cardiac canal were observed by transvaginal ultrasound. The gestational sac was confirmed as a clinical pregnancy feature, and the number of gestational sacs was recorded.
Anzeige
Statistical analysis
SPSS 27.0 (IBM) was used for statistical analyses. Continuous variables distribution was expressed as mean ± standard deviation and categorical variables were expressed as frequencies and percentages. Comparisons between groups were performed using one-way ANOVA, chi-square test, Fisher’s exact test, and nonparametric test. Logistic regression, presented as unadjusted odds ratio (crude odds ratio (OR)) or adjusted odds ratio (aOR) with a 95% confidence interval (CI), was performed. P < 0.05 was considered statistically significant.
Results
Patient characteristics
This retrospective cohort study was conducted in the Xingtai Infertility Specialist Hospital between January 2017 and November 2021. A total of 1,664 fresh ART cycles met inclusion criteria, including 242 PCOS and 1422 tubal factor transfers. Only patients who underwent fresh embryo transfer were included. The flowchart is shown in Fig. 1. The baseline characteristics of the PCOS and tubal groups are shown in Table 1. The age (P = 0.009) and AMH (P = 0.000) of the tubal group transferred on D3, D4, and D5 were different.
Table 1
Baseline characteristics of PCOS and tubal transferred cohorts on D3, D4, and D5
PCOS | P-value | Tubal | P-value | |||||
|---|---|---|---|---|---|---|---|---|
n = 242 | n = 1422 | |||||||
D3 | D4 | D5 | D3 | D4 | D5 | |||
Cycles | 81 | 117 | 44 | 486 | 768 | 168 | ||
Age (years) | 28.46 ± 3.97 | 29.00 ± 3.97 | 28.25 ± 3.50 | 0.421 | 30.26 ± 4.08* | 30.83 ± 3.86** | 30.01 ± 4.19 | 0.009 |
Type of infertility | 0.100 | 0.317 | ||||||
Primary | 69.14(56/81) | 59.83(70/117) | 72.73(32/44) | 27.78(135/486) | 26.95(207/768) | 32.74(55/168) | ||
Secondary | 30.86(25/81) | 40.17(47/117) | 27.27(12/44) | 72.22(351/486) | 73.05(561/768) | 67.26(113/168) | ||
Infertility duration (year) | 4.32 ± 2.93 | 4.63 ± 2.76 | 5.30 ± 2.98 | 0.192 | 3.48 ± 2.54 | 3.85 ± 2.90 | 3.52 ± 2.78 | 0.050 |
BMI (kg/m2) | 25.06 ± 3.10 | 25.71 ± 3.16 | 25.96 ± 2.92 | 0.217 | 23.37 ± 3.08 | 23.77 ± 3.21 | 23.60 ± 2.94 | 0.089 |
FSH (mIU/mL) | 6.01 ± 1.66 | 6.15 ± 1.79 | 5.93 ± 1.45 | 0.734 | 6.72 ± 2.25 | 6.71 ± 2.28 | 6.57 ± 1.70 | 0.730 |
AMH (ng/ mL) | 7.55 ± 4.82 | 7.77 ± 3.92 | 7.91 ± 3.20 | 0.884 | 3.21 ± 2.12* | 3.80 ± 2.28 | 3.93 ± 2.22*** | 0.000 |
Clinical characteristics and outcomes
As can be seen from Table 2, the Gn amount (P = 0.001), number of oocytes (P = 0.003), E2 of HCG (P = 0.014), number of embryos per ET cycle (P = 0.000), and endometrium thickness (P = 0.000) were different among D3, D4, and D5 of PCOS. The E2 of HCG was lowest, while the endometrium thickness was thickest in the D4 PCOS group (all P < 0.05). The outcomes of PCOS were different in pregnancy rate (P = 0.001), implantation rate (P = 0.000), miscarriage rate (P = 0.011), and live birth rate (P = 0.000) among D3, D4, and D5; It is apparent from this table that the pregnancy rate and live birth rate of D4 were higher than D3 and D5 transferred patients with PCOS (all P < 0.05). From this data, we also could see that the number of oocytes (P = 0.000) and E2 of HCG (P = 0.000) of tubal on D5 was highest in the three group days; The implantation rates of tubal on D4 and D5 were both higher than D3 (all P < 0.05).
Anzeige
Table 2
Stimulation characteristics and outcomes of PCOS and tubal transferred cohorts on D3, D4, and D5
PCOS | P-value | Tubal factor Infertility | P-value | |||||
|---|---|---|---|---|---|---|---|---|
n = 242 | n = 1422 | |||||||
D3 | D4 | D5 | D3 | D4 | D5 | |||
Cycles | 81 | 117 | 44 | 486 | 768 | 168 | ||
Gn(day) | 11.84 ± 2.80 | 11.88 ± 2.91 | 11.41 ± 2.71 | 0.628 | 11.60 ± 1.61 | 11.59 ± 1.82 | 11.63 ± 1.46 | 0.954 |
Gn amount (IU) | 2076.85 ± 767.48* | 2530.41 ± 1016.26** | 2114.77 ± 932.45 | 0.001 | 2511.86 ± 697.67 | 2537.42 ± 740.79 | 2451.04 ± 654.43 | 0.356 |
Number of oocytes | 14.68 ± 5.06 | 13.87 ± 4.80** | 16.98 ± 5.92*** | 0.003 | 11.44 ± 5.25* | 12.64 ± 4.73** | 14.63 ± 5.37*** | 0.000 |
Fertilization method | 0.500 | 0.775 | ||||||
IVF | 66.67(54/81) | 65.81(77/117) | 56.82(25/44) | 81.48(396/486) | 82.03(630/768) | 83.93(141/168) | ||
ICSI | 33.33(27/81) | 34.19(40/117) | 43.18(19/44) | 18.52(90/486) | 17.97(138/768) | 16.07(27/168) | ||
Available embryo rate, % | 43.86(325/741) | 42.61(496/1164) | 43.62(236/541) | 0.846 | 45.00(1599/3553) | 46.59(3222/6915) | 46.02(873/1897) | 0.303 |
E2 of HCG (pg/mL) | 3276.37 ± 1569.93 | 3141.89 ± 1363.39** | 3884.80 ± 1351.19*** | 0.014 | 2958.84 ± 1603.28* | 3142.54 ± 1436.51** | 3726.75 ± 1599.49*** | 0.000 |
P of HCG (ng/mL) | 0.64 ± 0.31 | 0.59 ± 0.22 | 0.63 ± 0.25 | 0.351 | 0.81 ± 0.31 | 0.79 ± 0.27 | 0.83 ± 0.30 | 0.216 |
Endometrium thickness(mm) | 10.49 ± 2.19* | 11.82 ± 2.10** | 11.37 ± 2.07*** | 0.000 | 11.29 ± 2.22 | 11.43 ± 2.14 | 11.7 ± 2.21 | 0.106 |
No. Of embryos per ET cycle | 2.00 ± 0.00* | 1.71 ± 0.46** | 1.55 ± 0.50*** | 0.000 | 1.98 ± 0.16* | 1.72 ± 0.45** | 1.57 ± 0.50*** | 0.000 |
Pregnancy rate, % | 51.85(42/81)* | 76.92(90/117)** | 61.36(27/44) | 0.001 | 60.91(296/486) | 63.02(484/768) | 61.31(103/168) | 0.735 |
Implantation rate, % | 35.19(57/162)* | 60(120/200) | 55.88(38/68)*** | 0.000 | 41.88(402/960)* | 49.01(646/1318) | 53.41(141/264)*** | 0.000 |
Ectopic pregnancy rate, % | 4.76(2/42) | 1.11(1/90) | 3.70(1/27) | 0.418 | 1.69(5/296) | 0.41(2/484) | 1.94(2/103) | 0.139 |
Miscarriage rate, % | 35.71(15/42)* | 13.33(12/90) | 25.93(7/27) | 0.011 | 15.54(46/296) | 14.46(70/484) | 16.50(17/103) | 0.837 |
Multiple pregnancy rate, % | 35.71(15/42) | 33.33(30/90) | 40.74(11/27) | 0.777 | 35.47(105/296) | 33.26(161/484) | 36.89(38/103) | 0.701 |
Live birth rate, % | 32.10(26/81)* | 65.81(77/117)** | 43.18(19/44) | 0.000 | 50.41(245/486) | 53.65(412/768) | 50.00(84/168) | 0.452 |
Subgroup analysis
Due to the age of tubal and the oocyte number of the two groups being different among D3, D4, and D5, we stratified patients by age and different oocytes in Tables 3 and 4, and 5. Interestingly, there were also coincided differences in the live birth rate of D4 in ≤ 30 years women with PCOS. There was a higher live birth rate on D4 than on D3 and D5 of PCOS (all P < 0.05). Although there was no statistically significant difference in live birth rates of the > 30 years group patients with PCOS, a similar trend was presented; When the number of oocytes was less than or equal to 20, the live birth rate was different among D3, D4, and D5 (all P < 0.05). The implantation rates of tubal (P = 0.006 and P = 0.027) were different in the two age stages (≤ 30 years and >30 years groups). In the different oocytes from tubal groups, the implantation rates were different among D3, D4, and D5 in numbers between 11 and 15 (P = 0.014) and more than 20 oocytes (P = 0.009) groups. With between 11 and 15 tubal oocytes, D5 had a greater implantation rate than D3 and D4 (all P < 0.05); With more than 20 tubal oocytes, D4 and D5 had a higher implantation rate than D3 (all P < 0.05) (Table 5).
Table 3
Outcomes of ≤ 30 years women with PCOS and tubal transferred cohorts on D3, D4, and D5
PCOS | P-value | Tubal factor Infertility | P-value | |||||
|---|---|---|---|---|---|---|---|---|
n = 170 | n = 705 | |||||||
D3 | D4 | D5 | D3 | D4 | D5 | |||
Cycles | 58 | 80 | 32 | 257 | 351 | 97 | ||
Age (years) | 26.48 ± 2.50 | 27.11 ± 2.63 | 26.56 ± 2.21 | 0.295 | 27.06 ± 2.31 | 27.42 ± 2.40 | 27.06 ± 2.66 | 0.137 |
Infertility duration (year) | 3.79 ± 1.86 | 4.15 ± 2.13 | 4.38 ± 2.46 | 0.885 | 3.17 ± 2.01 | 3.34 ± 2.14 | 3.39 ± 2.56 | 0.550 |
BMI (kg/m2) | 25.05 ± 3.14 | 25.25 ± 3.10 | 25.56 ± 3.04 | 0.648 | 23.26 ± 3.25 | 23.55 ± 3.34 | 23.50 ± 3.21 | 0.549 |
Endometrium thickness(mm) | 10.43 ± 2.08* | 11.84 ± 2.01 | 11.05 ± 1.94 | 0.000 | 11.28 ± 2.16 | 11.48 ± 2.05 | 11.69 ± 2.26 | 0.216 |
Pregnancy rate, % | 46.55(27/58)* | 78.75(63/80) | 62.50(20/32) | 0.000 | 62.26(160/257) | 66.10(232/351) | 68.04(66/97) | 0.489 |
Implantation rate, % | 31.90(37/116)* | 60.87(84/138) | 56.25(27/48)*** | 0.000 | 44.34(227/512)* | 51.72(315/609) | 57.05(89/156)*** | 0.006 |
Ectopic pregnancy rate, % | 7.41(2/27) | 1.59(1/63) | 5.00(1/20) | 0.376 | 2.50(4/160) | 0.86(2/232) | 1.52(1/66) | 0.430 |
Miscarriage rate, % | 29.63(8/27)* | 7.94(5/63) | 20.00(4/20) | 0.027 | 16.88(27/160) | 14.66(34/232) | 15.15(10/66) | 0.834 |
Multiple pregnancy rate, % | 37.04(10/27) | 33.33(21/63) | 35.00(7/20) | 0.943 | 41.25(66/160) | 35.34(82/232) | 34.85(23/66) | 0.446 |
Live birth rate, % | 31.03(18/58)* | 71.25(57/80)** | 46.88(15/32) | 0.000 | 50.19(129/257) | 55.84(196/351) | 56.70(55/97) | 0.323 |
Table 4
Outcomes of >30 years women with PCOS and tubal transferred cohorts on D3, D4, and D5
PCOS | P-value | Tubal factor Infertility | P-value | |||||
|---|---|---|---|---|---|---|---|---|
n = 72 | n = 717 | |||||||
D3 | D4 | D5 | D3 | D4 | D5 | |||
Cycles | 23 | 37 | 12 | 229 | 417 | 71 | ||
Age (years) | 33.86 ± 2.20 | 33.70 ± 2.12 | 34.04 ± 1.91 | 0.383 | 33.43 ± 2.25 | 33.08 ± 1.62 | 32.75 ± 1.91 | 0.578 |
Infertility duration (year) | 3.82 ± 2.99 | 4.28 ± 3.35 | 3.70 ± 3.06 | 0.136 | 5.65 ± 4.43 | 5.68 ± 3.60 | 7.75 ± 2.93 | 0.228 |
BMI (kg/m2) | 23.50 ± 2.87 | 23.96 ± 3.09 | 23.74 ± 2.56 | 0.169 | 25.10 ± 3.08 | 26.71 ± 3.10 | 27.03 ± 2.39 | 0.086 |
Endometrium thickness(mm) | 10.59 ± 2.38 | 11.76 ± 2.23 | 12.23 ± 2.24 | 0.084 | 11.26 ± 2.29 | 11.35 ± 2.24 | 11.60 ± 2.26 | 0.550 |
Pregnancy rate, % | 65.22(15/23) | 72.97(27/37) | 58.33(7/12) | 0.601 | 59.39(136/229) | 60.43(252/417) | 52.11(37/71) | 0.419 |
Implantation rate, % | 43.48(20/46) | 58.06(36/62) | 55.00(11/20) | 0.314 | 39.06(175/448)* | 46.69(331/709) | 48.15(52/108) | 0.027 |
Ectopic pregnancy rate, % | 0.00(0/15) | 0.00(0/27) | 0.00(0/7) | -- | 0.74(1/136) | 0.00(0/252) | 2.70(1/37) | 0.070 |
Miscarriage rate, % | 46.67(7/15) | 25.93(7/27) | 42.86(3/7) | 0.355 | 13.97(19/136) | 14.29(36/252) | 18.92(7/37) | 0.735 |
Multiple pregnancy rate, % | 33.33(5/15) | 33.33(9/27) | 57.14(4/7) | 0.481 | 28.68(39/136) | 31.35(79/252) | 40.54(15/37) | 0.386 |
Live birth rate, % | 34.78(8/23) | 54.05(20/37) | 33.33(4/12) | 0.240 | 50.66(116/229) | 51.80(216/417) | 40.85(29/71) | 0.232 |
Anzeige
Table 5
Outcomes of different oocytes retrieved from PCOS and tubal transferred on D3, D4, and D5
PCOS | P-value | Tubal factor Infertility | P-value | |||||
|---|---|---|---|---|---|---|---|---|
n = 242 | n = 1422 | |||||||
≤ 10 oocytes | D3 | D4 | D5 | D3 | D4 | D5 | ||
Cycles | 17 | 33 | 5 | 231 | 287 | 39 | ||
Pregnancy rate, % | 35.29(6/17) | 60.61(20/33) | 60.00(3/5) | 0.178 | 60.17(139/231) | 63.76(183/287) | 51.28(20/39) | 0.285 |
Implantation rate, % | 23.53(8/34)* | 50.00(28/56) | 57.14(4/7) | 0.032 | 40.18(182/453) | 47.64(242/508) | 45.76(27/59) | 0.065 |
Live birth rate, % | 29.41(5/17) | 54.55(18/33)** | 0.00(0/5) | 0.032 | 51.08(118/231) | 53.31(153/287) | 38.46(15/39) | 0.219 |
11–15 oocytes | ||||||||
Cycles | 29 | 41 | 18 | 156 | 277 | 66 | ||
Pregnancy rate, % | 58.62(17/29) | 75.61(31/41) | 55.56(10/18) | 0.196 | 62.18(97/156) | 61.01(169/277) | 68.18(45/66) | 0.557 |
Implantation rate, % | 43.10(25/58) | 61.11(44/72) | 53.57(15/28) | 0.123 | 42.07(130/309) | 47.33(230/486)** | 58.18(64/110)*** | 0.014 |
Live birth rate, % | 27.59(8/29)* | 65.85(27/41) | 38.89(7/18) | 0.005 | 47.44(74/156) | 52.35(145/277) | 60.61(40/66) | 0.195 |
16–20 oocytes | ||||||||
Cycles | 25 | 34 | 9 | 70 | 161 | 40 | ||
Pregnancy rate, % | 52.00(13/25)* | 91.18(31/34) | 77.78(7/9) | 0.003 | 70.00(49/70) | 69.57(112/161) | 55.00(22/40) | 0.186 |
Implantation rate, % | 32.00(16/50)* | 65.52(38/58) | 75.00(12/16)*** | 0.000 | 52.86(74/140) | 55.30(146/264) | 49.15(29/59) | 0.669 |
Live birth rate, % | 36.00(9/25)* | 73.53(25/34) | 55.56(5/9) | 0.016 | 60.00(42/70) | 60.87(98/161) | 40.00(16/40) | 0.051 |
>20 oocytes | ||||||||
Cycles | 10 | 9 | 12 | 29 | 43 | 23 | ||
Pregnancy rate, % | 60.00(6/10) | 88.89(8/9) | 58.33(7/12) | 0.272 | 37.93(11/29) | 46.51(20/43) | 69.57(16/23) | 0.067 |
Implantation rate, % | 40.00(8/20) | 71.43(10/14) | 41.18(7/17) | 0.144 | 27.59(16/58)* | 46.67(28/60) | 58.33(21/36)*** | 0.009 |
Live birth rate, % | 40.00(4/10) | 77.78(7/9) | 58.33(7/12) | 0.249 | 37.93(11/29) | 37.21(16/43) | 56.52(13/23) | 0.274 |
We further performed subgroup analysis by selecting high-quality embryos of ≤ 30 years women with PCOS and tubal in Table 6. Interestingly, the live birth rates were different in the three same-day transferred groups. The live birth rate of tubal was higher than PCOS on D3 (P = 0.032); The situation on D4 was the contrary, PCOS has a higher live birth rate than tuble (P = 0.031). There was no difference between them on D5 (Fig. 2).
Table 6
Outcomes of high quality embryos of ≤ 30 years women with PCOS and tubal transferred cohorts on D3, D4, and D5
D3 | P-value | D4 | P-value | D5 | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|
n = 100 | n = 271 | n = 97 | |||||||
PCOS | Tubal factor | PCOS | Tubal factor | PCOS | Tubal factor | ||||
Cycles | 22 | 78 | 54 | 217 | 27 | 70 | |||
Age (years) | 25.64 ± 2.52 | 26.13 ± 2.05 | 0.365 | 26.94 ± 2.82 | 27.24 ± 2.49 | 0.457 | 26.30 ± 2.16 | 27.21 ± 2.59 | 0.106 |
Infertility duration (year) | 4.45 ± 2.18 | 2.55 ± 1.64 | 0.000 | 3.98 ± 1.95 | 3.31 ± 2.06 | 0.028 | 3.93 ± 2.38 | 3.23 ± 2.02 | 0.151 |
BMI (kg/m2) | 24.95 ± 3.33 | 22.90 ± 3.35 | 0.015 | 25.41 ± 3.02 | 23.49 ± 3.25 | 0.000 | 25.58 ± 3.12 | 23.57 ± 3.21 | 0.007 |
Endometrium thickness(mm) | 9.97 ± 2.05 | 10.93 ± 2.27 | 0.085 | 12.08 ± 2.00 | 11.58 ± 1.98 | 0.093 | 11.14 ± 2.07 | 11.85 ± 2.09 | 0.139 |
Pregnancy rate, % | 54.55(12/22) | 70.51(55/78) | 0. 160 | 83.33(45/54) | 70.51(153/217) | 0.057 | 62.96(17/27) | 70.00(49/70) | 0.505 |
Implantation rate, % | 40.91(18/44) | 55.13(86/156) | 0.095 | 72.09(62/86) | 59.25(205/346) | 0.028 | 57.89(22/38) | 61.68(66/107) | 0.681 |
Ectopic pregnancy rate, % | 16.67(2/12) | 1.82(1/55) | 0.080 | 2.22(1/45) | 0.65(1/153) | 0.355 | 5.88(1/17) | 2.04(1/49) | 0.426 |
Miscarriage rate, % | 33.33(4/12) | 16.36(9/55) | 0 0.228 | 8.89(4/45) | 16.99(26/153) | 0.183 | 17.65(3/17) | 14.29(7/49) | 0.739 |
Multiple pregnancy rate, % | 50.00(6/12) | 56.36(31/55) | 0.688 | 37.78(17/45) | 33.99(52/153) | 0.639 | 29.41(5/17) | 34.69(17/49) | 0.691 |
Live birth rate, % | 31.82(7/22) | 57.69(45/78) | 0. 032 | 74.07(40/54) | 58.06(126/217) | 0.031 | 48.15(13/27) | 58.57(41/70) | 0.354 |
Fig. 2
Live birth rate and implantation rate of PCOS and tubal transferred cohorts on D3, D4, and D5
HQET: high quality embryos transferred
A: All PCOS, All Tubal, ≤ 30 years, PCOS, ≤ 30 years, Tuble and >30 years, Tubal, P<0.05
B: All PCOS and ≤ 30 years,PCOS, P<0.05
C: PCOS VS Tubal factor in D4, P<0.05
D: PCOS VS Tubal factor in D3 and D4, P<0.05
×
![]()
The associations of different transferred days and live birth rates of PCOS and tubal were shown in Table 7. What stands out in the table was the D4 of PCOS (unadjusted OR 2.533, 95% CI 1.247 to 5.143, P = 0.010; adjusted OR 3.328, 95% CI 1.532 to 7.229, P = 0.002) had a positively and significantly increased effort for live birth.
Table 7
Crude and adjusted odds ratios (ORs) of different transferred days for live birth rates
OR | 95%CI | P-value | OR | 95%CI | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|
PCOS | Crude | Tubal | Crude | ||||||
D5 | 1.000 | D5 | 1.000 | ||||||
D4 | 2.533 | 1.247–5.143 | 0.010 | D4 | 1.157 | 0.829–1.616 | 0.319 | ||
D3 | 0.622 | 0.292–1.326 | 0.219 | D3 | 1.017 | 0.716–1.444 | 0.927 | ||
Adjusted | Adjusted | ||||||||
D5 | 1.000 | D5 | 1.000 | ||||||
D4 | 3.328 | 1.532–7.229 | 0.002 | D4 | 1.194 | 0.851–1.675 | 0.304 | ||
D3 | 0.679 | 0.300-1.535 | 0.352 | D3 | 1.032 | 0.721–1.478 | 0.863 | ||
Discussion
According to this study, D4 transplanted patients had the highest live birth rate of PCOS patients. It might be not necessary to culture to blastocyst to optimize embryo transfer for PCOS women. This could be a novel way for PCOS patients to schedule their transplantation.
The primary goal of IVF-ET is the delivery of a healthy baby. ART has advanced over 40 years, yet the live birth rates remain poor [2]. PCOS patients are at a greater risk of pregnancy loss [16]. Many Pretreatment methods including GnRH agonist and hormone replacement treatment protocol, Metformin, and endometrial shedding with progestin before ovarian stimulation could not improve the live birth rate for PCOS women [17‐19]. Low embryo quality, aberrant uterine receptivity, and abnormal trophoblast invasion in PCOS women can predispose to low implantation, miscarriage, high risks of adverse birth outcomes, and low live birth rate [20‐22].
To select the most developing embryos, blastocyst culturing was used in IVF-ET. According to certain findings, transferring blastocyst-stage embryos increases the likelihood of a live delivery compared to transferring cleavage-stage embryos [23, 24]. However, there were significant drawbacks to blastocyst transfer, including a possible unbalanced sex ratio in favor of men and a higher risk of monozygotic twinning (MZT) [25]. According to recent data, elective single blastocyst and single morula embryo transfer in IVF-ET produced similar clinical results [8‐10]. The morula-stage embryo may have similar advantages compared to the blastocyst-stage embryo because it has both the activated embryonic genome [26]. The importance of Day 4 embryos in IVF should not be undervalued according to the literature [27, 28]. D4 good morula embryo transfer resulted in a compatible live birth rate with D5 blastocyst embryo transfer in fresh IVF/ET cycles [14], as well as similar pregnancy rate in an integrated time-lapse incubator [29‐31]. According to our research, transferred D4 and D5 of tubal or PCOS both had a higher implantation rate than D3 (all P < 0.05), which was consistent with before report [23]. We also found that the live birth rate of PCOS was higher on D4 than on D3 or D5 (all P < 0.05). However, there was no statistically significant difference in live birth rates among D3, D4, and D5 of tubal. The live birth rate of tubal was greater than PCOS on D3 and a lower live birth rate than PCOS on D4 of the same-day transferred groups in subgroup analysis by selecting high-quality embryos from women aged 30 years or younger (P < 0.05). The rate of live births differed between the tubal and PCOS. Recently, Wang et al. [32] found that the transfer of blastocyst-stage embryos was associated with shorter leukocyte telomere length (LTL) in children than the transfer of cleavage-stage embryos. It implied a better reason to transfer D4 than D5.
Successful implantation requires endometrial receptivity status for embryo localization, adhesion, invasion, and implantation. Notably, whether its tolerance synchronous alteration with the growth of the embryo is key to determining implantation. Synchronous coordination of the endometrial receptivity status and embryonic development is necessary for successful implantation.
In this study, we found the tubal and PCOS have differences in live birth rates undergoing IVF-ET. This may reflect the differences between the endometrial receptivity of tubal and PCOS during COH. It was reported that COH might negatively affect endometrial receptivity [33] for implantation [34]. Ovarian stimulation for IVF profoundly alters the luteal phase of endometrial development. Zapantis et al. [35] reported the premature appearance of the nucleolar channel system (NCS) and hence maturation of the endometrium following COH [36]. Exogenous gonadotropin in IVF decreased the implantation rate [37]. The mTOR signaling might be involved in the effect of maternal hyperinsulinemia on the endometrium receptivity process [38]. PCOS has unusual levels of hormones. The hormone receptors in the endometrium have a hostile effect and make the microenvironment unfavorable for embryo implantation. The endometrial receptivity of PCOS was closely associated with gene expression, energy metabolism, and endocrine environment [39]. The cell cycle was the fundamental biological process dysregulated in the endometrium of PCOS women, affecting decidualization progression in the endometrium during the implantation window [40]. Zhang et al. [41] discovered that as PCOS worsens, alterations in various signal pathways may decrease endometrial receptivity and reproductive outcomes.
Embryo-endometrium synchronization is important in embryo transfer. A study demonstrated abnormal gene expression in human PCOS oocytes. These genes included processes such as maternal effect genes and the mitotic cell cycle [42]. It has been shown that the time to initiate compaction and reach the morula stage as well as the duration of the 4th cleavage division was significantly shorter in PCOS embryos compared with non-PCOS embryos [43]. Moreover, it was observed that faster embryonic growth in PCOS preimplantation embryos, and there appear to be worse obstetric outcomes for these patients [44]. Given the maturity of endometrium following COH [36], it appeared that transfer on D4 was a good decision, particularly for PCOS.
A study thought that serum E2 levels on the day of trigger were not a good predictor of live birth rate or perinatal and obstetrical outcomes [45]. However, the other studies thought that peak E2 level on hCG trigger day was associated with the cumulative live birth rate (cLBR) in a segmental pattern [46]. Our results showed that the E2 of HCG among D3, D4, and D5 were all different in PCOS and tubal groups (all P < 0.05). Since estrogen matched with the number of oocytes retrieved, we chose the number of eggs collected for group analysis to avoid statistical errors. Our results showed that the implantation rate of tubal oocyte numbers between 11 and 15 were different in three transferred days (P = 0.014). D5 had a higher implantation rate than D3 and D4 of tubal oocytes between 11 and 15 (all P < 0.05); The live birth rate of PCOS was higher on D4 than D3 when oocytes number between 11 and 20 (all P < 0.05). The results of this study showed that D4 of PCOS (unadjusted OR 2.533, 95% CI 1.247 to 5.143, P = 0.010; adjusted OR 3.328, 95% CI 1.532 to 7.229, P = 0.002) had a positively and significantly increased effort for live birth. Those might imply that PCOS transferred on D4 were better, especially the live birth rate.
The outcomes of PCOS were different from tubal. The reasons for this conclusion may be: First, it should be noted that PCOS had a lower endometrial receptivity than tubal. Additionally, ovarian stimulation changed how the endometrial luteal phase developed and appeared to affect receptivity for implantation. The premature appearance of the NCS and hence maturation of the endometrium following COH [27]. Also, it has been reported that morulae and blastocysts have similar advantages. They both have activated embryonic genomes and are more synchronized with the endometrium than D3 cleavage embryos [39]. Added faster embryonic growth in PCOS preimplantation embryo [44], it could be the implant window of PCOS during COH earlier than the fallopian tube. The embryo quality, embryo-endometrial synchrony, and altered gene expression during the window of implantation were important for the implantation and live birth. Those might imply that PCOS transferred on D4 were better, especially the live birth rate. A prospective randomized control experiment is also required to verify the findings.
Strengths and limitations
The main benefit of our study was that it investigated the outcomes of PCOS and oviduct factor infertility in different transferred days of D3, D4, and D5. This study does, however, have some limitations since it was a retrospective single-center study. Efforts to boost the patients’ pregnancy rate at the time, we transplanted more embryos than now when P ≤ 1.5 ng/mL (99.28% of the entire cycle). This resulted in a high multiple pregnancy rate. We have now been able to reduce the number of transplant as well as the multiple pregnancy rate since realizing this problem. Moreover, we cannot exclude bias due to different ethnicities. Further multi-center randomized clinical trials would be needed for confirmation. In addition, due to the nature of the study unknown confounding factors cannot be excluded. Prospective randomized control trials should be addressed in the future to investigate the best day for transfer.
Conclusion
In conclusion, the current study showed that live birth rates of PCOS were different on various transferred days. The highest live birth rate of PCOS patients was on D4 transferred. These results suggested that it was not need to culture embryos to blastocysts to optimize embryo transfer for PCOS women. This may be a new transplantation strategy for PCOS.
Acknowledgements
The authors thank the medical staff.
Declarations
Ethics approval and consent to participate
The study was approved by the research ethics board at Xingtai Reproduction and Genetics Specialist Hospital (Protocol number 202112). All participating patients signed written informed consent. The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Conflict of interests
All authors declare no potential conflicts of interest concerning the research, authorship, and/or publication of this article.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.